# Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

> **NCT00580216** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 3773 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Idrabiotaparinux sodium
- **DRUG:** Warfarin
- **DRUG:** Placebo (for idrabiotaparinux)
- **DRUG:** Placebo (for warfarin)
- **DRUG:** Avidin
- **DRUG:** Placebo (for avidin)

## Key facts

- **NCT ID:** NCT00580216
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 3773 (ACTUAL)
- **Why stopped:** early discontinuation based on strategic sponsor decision not driven by any safety concern
- **Last updated:** 2016-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580216, "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00580216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*